A1=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg)

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

3 competitors in Type 2 Diabetes

Drug Information

Target Indication

Type 2 Diabetes

Clinical Trial

Last updated: 1/22/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

LRVIY

Laboratorios Farmaceuticos Rovi, S.A./ADR

Related Pipeline

Allergic Rhinoconjunctivitis

Osteoarthritis of Knee

Alopecia

Influenza, Human

Arterial Hypertension